NFKB1 and lung carcinoma: In our study, PCA-BSA@FA-NPs treatment significantly reduced NF-κB levels by 2.79-fold in the lung tissue compared to the PCA-treated group, indicating its effectiveness in inhibiting lung cancer proliferation.